This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Respiratory Syncytial Virus (RSV)
  • /
  • A Phase III Double-blind Study to Assess Safety an...
Clinical trial

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

Read time: 1 mins
Last updated:14th Nov 2021
Status: Recruiting
Identifier: NCT04605159
A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)


The purpose of this study is to evaluate the ability of a single dose of the investigational RSV Maternal vaccine, administered intramuscularly to pregnant women aged 18-49 years, in good general maternal health, in preventing medically assessed RSV associated Lower Respiratory Tract Illnesses (LRTIs) in infants born to vaccinated mothers. The study will also evaluate the safety of the investigational RSV Maternal vaccine both in vaccinated mothers and in their corresponding infant.


Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 20000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Actual Study Start Date: November 20, 2020
Estimated Primary Completion Date: August 1, 2023
Estimated Study Completion Date: February 2, 2024

Arm:
- Experimental: RSV_MAT Group
- Placebo Comparator: Control Group

Category Value
Study type(s) Interventional
Estimated enrolment 20000
Actual Study start date 20 November 2020
Estimated Study Completion Date 02 February 2024

View full details